$PDSB
PDS Biotechnology Corp

2023 Q4 Form 10-Q Financial Statement

#000114036123053242 Filed on November 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.941M $4.070M
YoY Change 10.31% 39.09%
% of Gross Profit
Research & Development $7.466M $6.449M
YoY Change -53.79% 48.14%
% of Gross Profit
Depreciation & Amortization $17.33K $10.00K
YoY Change 49.65% -73.27%
% of Gross Profit
Operating Expenses $10.41M $10.52M
YoY Change -44.71% 44.52%
Operating Profit -$10.52M
YoY Change 44.52%
Interest Expense -$491.3K $1.069M
YoY Change -835.87%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$10.90M -$10.85M
YoY Change -43.05% 46.13%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$10.90M -$10.85M
YoY Change -43.05% 46.13%
Net Earnings / Revenue
Basic Earnings Per Share -$0.35
Diluted Earnings Per Share -$0.34 -$0.35
COMMON SHARES
Basic Shares Outstanding 31.11M 30.87M
Diluted Shares Outstanding 30.91M

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $56.56M $54.30M
YoY Change -23.38% -24.21%
Cash & Equivalents $56.56M $54.30M
Short-Term Investments
Other Short-Term Assets $2.495M $2.600M
YoY Change -6.23% -6.1%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $59.06M $56.84M
YoY Change -22.78% -23.62%
LONG-TERM ASSETS
Property, Plant & Equipment $335.0K $138.9K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $335.0K $349.4K
YoY Change -36.5% -26.5%
TOTAL ASSETS
Total Short-Term Assets $59.06M $56.84M
Total Long-Term Assets $335.0K $349.4K
Total Assets $59.39M $57.19M
YoY Change -22.88% -23.63%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.983M $5.367M
YoY Change 472.7% 163.4%
Accrued Expenses $2.425M $3.733M
YoY Change -70.84% 53.7%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $4.222M $100.0K
YoY Change 7358.86% 63.21%
Total Short-Term Liabilities $13.63M $9.154M
YoY Change 38.78% 89.08%
LONG-TERM LIABILITIES
Long-Term Debt $19.63M $23.60M
YoY Change -15.34% 2.67%
Other Long-Term Liabilities $0.00
YoY Change
Total Long-Term Liabilities $19.63M $23.60M
YoY Change -15.34% 2.67%
TOTAL LIABILITIES
Total Short-Term Liabilities $13.63M $9.154M
Total Long-Term Liabilities $19.63M $23.60M
Total Liabilities $33.26M $32.70M
YoY Change 0.77% 17.52%
SHAREHOLDERS EQUITY
Retained Earnings -$144.5M -$133.6M
YoY Change 42.28% 62.1%
Common Stock $10.92K $10.23K
YoY Change 9.69% 8.97%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $26.13M $24.48M
YoY Change
Total Liabilities & Shareholders Equity $59.39M $57.19M
YoY Change -22.88% -23.63%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$10.90M -$10.85M
YoY Change -43.05% 46.13%
Depreciation, Depletion And Amortization $17.33K $10.00K
YoY Change 49.65% -73.27%
Cash From Operating Activities -$8.456M -$7.180M
YoY Change 12.32% 21.84%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 10.77M 800.0K
YoY Change 10.92% -96.74%
NET CHANGE
Cash From Operating Activities -8.456M -7.180M
Cash From Investing Activities
Cash From Financing Activities 10.77M 800.0K
Net Change In Cash 2.310M -6.380M
YoY Change 6.09% -134.19%
FREE CASH FLOW
Cash From Operating Activities -$8.456M -$7.180M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
152645
CY2023Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
54537
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
8849
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
08540
dei City Area Code
CityAreaCode
800
dei Local Phone Number
LocalPhoneNumber
208-3343
dei Security12b Title
Security12bTitle
Common Stock, par value $0.00033 per share
dei Trading Symbol
TradingSymbol
PDSB
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
0
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5890131
dei Entity Registrant Name
EntityRegistrantName
PDS Biotechnology Corp
dei Entity Address Address Line1
EntityAddressAddressLine1
303A College Road East
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
31107763
CY2022Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
56612
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
231429
CY2023Q3 us-gaap Interest Expense
InterestExpense
1068887
CY2022Q3 us-gaap Interest Expense
InterestExpense
397327
us-gaap Interest Expense
InterestExpense
3031129
us-gaap Interest Expense
InterestExpense
397326
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1406021
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1198905
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
7488
CY2023Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
610000
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
243743
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
610000
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
0
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9900000
CY2023Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
139575
us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
736037
CY2023Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
800000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5600000
CY2023Q2 pdsb Proceeds From Sale Of Unused Net Operating Loss Carryforwards
ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards
1400000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
54300000
CY2022Q2 pdsb Proceeds From Sale Of Unused Net Operating Loss Carryforwards
ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards
1200000
CY2022Q3 pdsb Shelf Registration Statement Available For Future Sale
ShelfRegistrationStatementAvailableForFutureSale
150000000
CY2022Q3 pdsb Placement Shares Available For Future Sale
PlacementSharesAvailableForFutureSale
50000000
CY2022Q3 pdsb Placement Shares Available For Future Sale
PlacementSharesAvailableForFutureSale
50000000
CY2022Q3 pdsb Commission Percentage
CommissionPercentage
0.03
CY2022 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
1238491
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001472091
dei Document Type
DocumentType
10-Q
dei Entity File Number
EntityFileNumber
001-37568
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-4231384
dei Entity Address City Or Town
EntityAddressCityOrTown
Princeton
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10849169
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7424450
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-33450003
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-22916077
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1344349
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
1713714
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-7424450
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
47058836
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2073607
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
815202
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-10849169
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
24483828
pdsb Increase Decrease In Finance Lease Right To Use Asset
IncreaseDecreaseInFinanceLeaseRightToUseAsset
0
pdsb Increase Decrease In Finance Lease Right To Use Asset
IncreaseDecreaseInFinanceLeaseRightToUseAsset
306487
pdsb Increase Decrease In Finance Lease Liabilities
IncreaseDecreaseInFinanceLeaseLiabilities
0
pdsb Increase Decrease In Finance Lease Liabilities
IncreaseDecreaseInFinanceLeaseLiabilities
138402
us-gaap Proceeds From Issuance Of Secured Debt
ProceedsFromIssuanceOfSecuredDebt
0
us-gaap Proceeds From Issuance Of Secured Debt
ProceedsFromIssuanceOfSecuredDebt
25000000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
449329
pdsb Fair Value Of Warrants Issued In Connection With Debt
FairValueOfWarrantsIssuedInConnectionWithDebt
0
pdsb Fair Value Of Warrants Issued In Connection With Debt
FairValueOfWarrantsIssuedInConnectionWithDebt
1713741
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4877075
CY2023Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
54251387
CY2022Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
73820160
CY2023Q3 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
11200
CY2023Q3 us-gaap Lessor Operating Lease Term Of Contract
LessorOperatingLeaseTermOfContract
P40M
CY2020Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
700000
CY2020Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
700000
CY2020Q2 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.0915
us-gaap Operating Lease Payments
OperatingLeasePayments
239469
us-gaap Operating Lease Payments
OperatingLeasePayments
205885
pdsb Finance Lease Principal And Interest Payments
FinanceLeasePrincipalAndInterestPayments
60684
pdsb Finance Lease Principal And Interest Payments
FinanceLeasePrincipalAndInterestPayments
306487
CY2023Q3 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
17464
CY2023Q3 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
69850
CY2023Q3 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
69850
CY2023Q3 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
40108
CY2023Q3 pdsb Finance Lease Liability To Be Paid Year Four And Thereafter
FinanceLeaseLiabilityToBePaidYearFourAndThereafter
26724
CY2023Q3 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
223996
CY2023Q3 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
32058
CY2023Q3 us-gaap Finance Lease Liability
FinanceLeaseLiability
191938
pdsb Lessee Finance Lease Number Of Leases
LesseeFinanceLeaseNumberOfLeases
4
pdsb Finance Lease Cost
FinanceLeaseCost
251959
CY2023Q3 us-gaap Lessee Finance Lease Discount Rate
LesseeFinanceLeaseDiscountRate
0.0915
pdsb Lessee Finance Lease Monthly Rental Expense
LesseeFinanceLeaseMonthlyRentalExpense
6000
us-gaap Property Plant And Equipment Additions
PropertyPlantAndEquipmentAdditions
151490
CY2023Q3 pdsb Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
79910
CY2022Q4 pdsb Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
5645737
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1570401
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
550259
CY2023Q3 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
1785173
CY2022Q4 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
1837330
CY2023Q3 us-gaap Interest Payable Current
InterestPayableCurrent
296875
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
280382
CY2023Q3 us-gaap Accrued Rent Current
AccruedRentCurrent
368
CY2022Q4 us-gaap Accrued Rent Current
AccruedRentCurrent
0
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3732727
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8313708
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.5026
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.0143
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.4247
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.9956
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0392
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0303
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0404
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.017
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y7M2D
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y29D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y21D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y4M28D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.77
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.58
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
10.35
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.8
us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
0
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023Q3 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023Q3 pdsb Liability For Uncertain Tax Positions
LiabilityForUncertainTaxPositions
0
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2023Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2022Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2023Q3 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1400000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1200000
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
106171
us-gaap Operating Lease Cost
OperatingLeaseCost
359373
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
55500
us-gaap Operating Lease Cost
OperatingLeaseCost
165500
CY2022Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
381625
CY2022Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
3.6685
CY2023Q3 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P10Y
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
449329
CY2023Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
2524736
CY2023Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
1064300
us-gaap Interest Expense Debt
InterestExpenseDebt
3016572
CY2023Q3 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
158397
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
391920
CY2023Q3 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
32861
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
164631
CY2022Q3 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
31515
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
119232
CY2023Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0001140361-23-053242-index-headers.html Edgar Link pending
0001140361-23-053242-index.html Edgar Link pending
0001140361-23-053242.txt Edgar Link pending
0001140361-23-053242-xbrl.zip Edgar Link pending
ef20012461_10q.htm Edgar Link pending
ef20012461_ex31-1.htm Edgar Link pending
ef20012461_ex31-2.htm Edgar Link pending
ef20012461_ex32-1.htm Edgar Link pending
ef20012461_ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image01.jpg Edgar Link pending
image02.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
pdsb-20230930.xsd Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
pdsb-20230930_cal.xml Edgar Link unprocessable
pdsb-20230930_def.xml Edgar Link unprocessable
pdsb-20230930_lab.xml Edgar Link unprocessable
pdsb-20230930_pre.xml Edgar Link unprocessable
ef20012461_10q_htm.xml Edgar Link completed
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending